Ocular surface and lid margin bacteria; ocular surface lubrication

The entry "Ocular surface/lid margin bacteria via antibacterial action of methylglyoxal in manuka honey; ocular surface lubrication via glycerin" does not refer to a single molecular target or receptor. Instead, it describes two therapeutic strategies for managing dry eye disease and related conditions: 1. **Antibacterial action** against *ocular surface* and *lid margin* bacteria is achieved through the use of manuka (*Leptospermum* spp.) honey, specifically due to its content of methylglyoxal—a compound with proven bactericidal properties that can reduce bacterial load implicated in blepharitis and meibomian gland dysfunction[3][5]. Manuka honey-based ophthalmic preparations have demonstrated safety and efficacy as adjunctive treatments for these conditions. 2. **Ocular surface lubrication** is provided by glycerin (glycerol), which acts as a humectant, osmoprotectant, lubricant, and tear film stabilizer—helping alleviate symptoms associated with dry eye disease by retaining moisture on the ocular surface, reducing evaporation rate, protecting epithelial cells from hyperosmolarity-induced damage, and possibly exerting anti-inflammatory effects[2][6]. Neither "ocular surface/lid margin bacteria" nor "ocular surface lubrication" are canonical molecular targets such as receptors or enzymes; rather they are physiological sites/processes affected by these therapies. The actual active agents—methylglyoxal (from manuka honey) for antibacterial effect and glycerin for lubrication—are not themselves considered classical drug targets but rather therapeutic agents acting on broader biological processes. This entry should be flagged as incorrect if intended to represent a specific molecular target or receptor suitable for structured pharmacological databases.

Antibacterial action via methylglyoxal in manuka honey; ocular surface lubrication and osmoprotection via glycerin